Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitors Versus Regorafenib Plus PD-1 Inhibitors in Refractory Microsatellite Stable Metastatic Colorectal Cancer
Li‐Ying Sun(Ministry of Education of the People's Republic of China), Jianbing Wu(Nanchang University)
Cited by 39
Related Papers
Differential susceptibility to carbapenems due to the AdeABC efflux pump among nosocomial outbreak isolates of Acinetobacter baumannii in a Chinese hospital
|Diagnostic Microbiology and Infectious Disease|2008|56
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
|The Lancet. Gastroenterology & hepatology|2025|39